Fingolimod for the treatment of neurological diseases-state of play and future perspectives - Wikidata - wikimedia - TriplyDB

Fingolimod for the treatment of neurological diseases-state of play and future perspectives

Fingolimod for the treatment of neurological diseases-state of play and future perspectives

http://www.wikidata.org/entity/Q27026175

about

Sphingosine 1-phosphate signaling pathway in inner ear biology. New therapeutic strategies for hearing loss?Fingolimod Limits Acute Aβ Neurotoxicity and Promotes Synaptic Versus Extrasynaptic NMDA Receptor Functionality in Hippocampal Neurons Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1.Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage.The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice.Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy Neuroinflammatory paradigms in lysosomal storage diseases.Regulatory T Cell Immunotherapy in Immune-Mediated Diseases Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients.Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke.Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects.Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis.Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion.Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model.Altered Sphingolipid Balance in Capillary Cerebral Amyloid Angiopathy.Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.Critical Role of the Sphingolipid Pathway in Stroke: a Review of Current Utility and Potential Therapeutic Targets.Clinical Trials of Immunomodulation in Ischemic Stroke.Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.Nuclear Lipids in the Nervous System: What they do in Health and Disease.Crosstalk between sphingolipids and vitamin D3: potential role in the nervous system.Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory.Neuronal plasticity and neurotrophic factors in drug responses.Editorial: Mechanisms of neuroinflammation and inflammatory neurodegeneration in acute brain injury.Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models.Fingolimod confers neuroprotection through activation of Rac1 after experimental germinal matrix hemorrhage in rat pups.Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.Clinical studies and anti-inflammatory mechanisms of treatments.Alteration of sphingolipid metabolism as a putative mechanism underlying LPS-induced BBB disruption.A Three-Day Consecutive Fingolimod Administration Improves Neurological Functions and Modulates Multiple Immune Responses of CCI Mice.Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System.Fingolimod hydrochloride gel shows promising therapeutic effects in a mouse model of atopic dermatitis.Calcitonin physiology, saved by a lysophospholipid.The “inflammatory penumbra” in ischemic stroke: From clinical data to experimental evidence Peripheral T Cell Depletion by FTY720 Exacerbates Hypoxic-Ischemic Brain Injury in Neonatal Mice

P2860

Q27024207-ACA80452-C885-4CED-AF99-A38D64EACE2E Q30836800-D9867450-28D6-4D67-9094-C0E41D1398F1 Q33620206-BFEA7592-14A3-45B4-A202-644D43E56017 Q35074224-5CEFE15A-9E30-41FF-9631-0E175D34EE89 Q35666531-B608EE33-9997-4564-8D13-B5505DF04AA7 Q35976992-CB542AB1-2428-47A7-9665-1C406DC5D5E5 Q36232187-47FF881C-C882-40E9-9934-26A3D22B18C4 Q36462109-BD9F6A7B-56A5-4B6C-BC18-CA080898C45E Q36529526-648C2F17-1628-4B97-91F8-8E8A8760F8BE Q37209163-CB0D2F4F-46C9-4D3D-9F89-914A8A5394AA Q37228601-30D9A8A1-05B5-4211-9B34-CC418296CD56 Q38639875-8C02CEF3-4CFA-46AF-9AB4-68814F379536 Q38669047-4515A97C-532B-43F2-911B-B90A7F79FA04 Q38707729-0A8A8C1C-81AF-4DF1-BB76-E815C85C4CEE Q38818321-0B50A79D-7998-4FE5-A670-809F7476DEBA Q38869471-F3AD3B94-E836-44BF-9821-372A7CC9B8C9 Q38875349-CD824814-7852-45ED-9141-61C14029D398 Q38895854-D37EBA79-218A-4F9E-AA7F-CEB0447B68DB Q38983628-2E3DCEA2-4288-4F94-9894-9C10C7F60C27 Q38986890-E28F5388-85B3-4E3B-858C-451C65275892 Q39106107-5CB7FEC9-AA83-4820-840A-36FF29B39015 Q41270868-A246DFD9-B131-437E-9EC0-846E73887EA9 Q41842609-77400689-EFD0-4CBD-AB16-E06AAE903F22 Q42118560-56CE1E3D-38FC-4F43-8FB5-BFBDE476B436 Q42234408-9E44C89F-FD0A-4773-A9A9-33D15084A447 Q45299524-110B42AB-DA54-4B61-80A9-796E9A1814DC Q46079105-F3B95E8E-BB8B-4B30-90E2-493EEFF2A665 Q46444617-7AADE25A-8D38-41DB-BB7B-A78879E3E7D9 Q47124754-9C3656FE-B108-473F-8BBE-F9D458DF6CB5 Q48022739-C963AACD-B0D9-4203-B850-4A4E2413EC8F Q48403817-BD6C1A59-ED21-4088-ACFE-B26105675E19 Q51765579-C720973E-28B0-4488-84B6-0EB8188DE632 Q52857967-77334A62-FB79-4821-B776-767D4D602DAA Q53646257-B1A5D3A3-9F95-42B9-A097-C88F9A46B62F Q58179746-71803BA7-8CC9-428A-880D-98E21B22A3B9 Q58799094-F5649CB5-1A62-475F-AD7B-5AB868DD834D

P2860

Fingolimod for the treatment of neurological diseases-state of play and future perspectives

http://www.wikidata.org/entity/Q27026175

description

2014 nî lūn-bûn

@nan

2014 թուականին հրատարակուած գիտական յօդուած

@hyw

2014 թվականին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Fingolimod for the treatment o ...... f play and future perspectives

@ast

Fingolimod for the treatment o ...... f play and future perspectives

@en

Fingolimod for the treatment o ...... f play and future perspectives

@nl

type

label

Fingolimod for the treatment o ...... f play and future perspectives

@ast

Fingolimod for the treatment o ...... f play and future perspectives

@en

Fingolimod for the treatment o ...... f play and future perspectives

@nl

prefLabel

Fingolimod for the treatment o ...... f play and future perspectives

@ast

Fingolimod for the treatment o ...... f play and future perspectives

@en

Fingolimod for the treatment o ...... f play and future perspectives

@nl

P1433

Q27026175-B66A8EA4-C146-4688-A788-798993B7ACD4

P1476

Q27026175-8AF60E91-6CF7-425A-A987-917608A4562D

P2093

Q27026175-009BA9FF-F4FF-472D-8EA6-AC25D133A4E3

Q27026175-C0BB60C0-2869-4B7A-B8EE-3AF5F1D8F7A7

Q27026175-D0DAA5D4-7155-4003-85B7-898311BC2D46

P2860

Q27026175-025B7939-4A80-451F-AA23-024A84019C8E

Q27026175-03C985F1-3D34-4B60-B851-EB4C5752B1C9

Q27026175-043742AD-FE23-4561-9FA4-FB18F84BEC6C

Q27026175-048716F2-9AF0-4650-ADF5-56673C52CA71

Q27026175-053D86A2-2332-412F-9DBB-BD7ED05B5974

Q27026175-0580EB84-14F1-4A28-B650-E05452AA65FA

Q27026175-08B1AA7C-D2B4-4316-BEC4-48FE83FBA810

Q27026175-09A3E410-2F4E-46EC-92E2-69218ADBEE88

Q27026175-09C08605-5FB1-4CE3-914B-3104E8072871

Q27026175-0A3CF856-7B99-4241-8826-C9F8D237521C

P304

Q27026175-0C428471-7493-4098-AEC8-77B84CAE2B8C

P31

Q27026175-B8EEF9DF-949F-43E8-AE21-6D94B0A1DE7E

P3181

Q27026175-8633BB65-A0DE-4863-999D-3ACC9C40D3B7

P356

Q27026175-28993FBD-9FC8-4046-B284-4C5A194F5162

P407

Q27026175-29C3D7FC-8538-4C35-A888-11BD48D80147

P478

Q27026175-57DC63B2-11EE-40F8-95A5-63C51D2CC10D

P577

Q27026175-2B3E4AA0-281A-40C6-9A68-32B83FF31BA0

P5875

Q27026175-6FFF74FA-E889-4F40-BE66-2A08053B8A7F

P698

Q27026175-16E9743B-60FC-4C1A-93BF-04AA9E70DC6F

P932

Q27026175-1DAF77EF-5F9E-4AD9-ADAC-6D48B96B7C41

P3181

P356

FNCEL.2014.00283

P1433

Frontiers in Cellular Neuroscience

P1476

Fingolimod for the treatment o ...... f play and future perspectives

@en

P2093

Rajkumar Vutukuri

http://www.w3.org/2001/XMLSchema#string

Robert Brunkhorst

http://www.w3.org/2001/XMLSchema#string

Waltraud Pfeilschifter

http://www.w3.org/2001/XMLSchema#string

P2860

Temozolomide for high grade glioma

Temozolomide for High Grade Glioma

Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2

T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.

S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress

The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

S1P control of endothelial integrity

Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond

FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke

P304

283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3859692

http://www.w3.org/2001/XMLSchema#string

P356

10.3389/FNCEL.2014.00283

http://www.w3.org/2001/XMLSchema#string

P407

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266950475

http://www.w3.org/2001/XMLSchema#string

P698

25309325

http://www.w3.org/2001/XMLSchema#string

P932

4162362

http://www.w3.org/2001/XMLSchema#string